✦ LIBER ✦

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

✍ Scribed by Soria, Jean Charles; Massard, Christophe; Lazar, Vladimir; Ozoux, Marie-Laure; Mery-Mignard, Dominique; Deslandes, Antoine; Tolcher, Anthony W.

Book ID: 125441194
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 358 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.01.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 pharmacokinetic study of MK-0646

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

✍ Doi, Toshihiko; Muro, Kei; Yoshino, Takayuki; Fuse, Nozomu; Ura, Takashi; Takaha 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 517 KB

196 POSTER A phase I trial incorporating

196 POSTER A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer

✍ P.C. Fong; R.L. Molife; J. Spicer; T.A. Yap; S. Settatree; L. Digue; G. Attard; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Safety, Tolerability, Pharmacokinetics a

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

✍ Okusaka, T.; Ikeda, M.; Fukutomi, A.; Kobayashi, Y.; Shibayama, K.; Takubo, T.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 157 KB